美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Franklin Genomic Advancements ETF

41.87

+0.04560.11%

成交量：96

成交額：4,036

市值：3,140.47萬

市盈率：- -

高：41.87

開：41.83

低：41.87

收：41.83

52周最高：43.51

52周最低：29.80

股本：75.00萬

流通股本：75.00萬

量比：0.25

換手率：0.01%

股息：0.14

股息率：0.34%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

Twinstrand：法院判決公司及Uw獲賠逾2.452億美元，涵蓋截至2026年5月31日的侵權損害賠償、應計特許權使用費及利息

Twinstrand勝訴：法院維持2023年故意侵權判決，並裁定Guardant Health 11項產品與服務須支付6%特許權使用費

Twinstrand案判決：Guardant Health須按季度向公司及承銷商彙報11款產品與服務的全美銷售明細

Twinstrand：特拉華州法院於8月21日裁定公司及華盛頓大學在針對Guardant Health的專利侵權訴訟中勝訴

A股異動 | 華大智造(688114.SH)早盤漲20%封漲停基因測序有望成為mRNA個性化腫瘤疫苗「底層基礎設施「

第3次更新-足球——謝菲爾德聯隊前所有者獲准申請清算當初收購該俱樂部的那家公司

Natera助力新臨床研究：利用Latitude™評估晚期皮膚癌ctDNA動態變化

韓國公布七項戰略技術項目涵蓋核能、量子計算、太空、生物技術等領域

我國綠色燃料產業從「示範試點」走向「規模量產」

中賦科技成立靈源生物技術公司

風暴眼 | 6歲女童基因治療死亡：急於追逐「全球首例」的代價

凤凰网港股

半月內兩起兒童基因編輯試驗死亡事件曝光，業內警示：追求「全球首創」不能忽視臨床安全與合規要求

新聞8點見丨影院屏攝亂象背後的三角困局；女童基因編輯悲劇中倫理為何失守

AI賦能肺癌早篩診療升級國產醫療機器人加速精準醫療落地真健康醫療(02697)迎行業發展機遇

港股異動 | 凱萊英升逾8%，近日擬向上海凱萊英生物技術發展增資10.5億元

專注腫瘤領域的生物技術公司BlossomHill Therapeutics計劃通過首次公開募股募資約1.328億美元。

基因編輯的商業化：一款產品220萬美元，A股超20家概念股，但多數只賣工具

红星资本局

市場消息：日本政府計劃將西日本打造為生物技術與高端醫藥領域的投資集聚中心。

凱萊英(06821)擬向上海凱萊英生物技術發展增資10.5億元

凱萊英(06821.HK)擬向上海凱萊英生物技術發展增資10.5億元

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/HELX/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"HELX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELX\",,,,,undefined,":{"symbol":"HELX","market":"US","secType":"STK","nameCN":"Franklin Genomic Advancements ETF","latestPrice":41.8729,"timestamp":1789588800000,"preClose":41.8273,"halted":0,"volume":96,"delay":0,"changeRate":0.0010901970722470805,"floatShares":750000,"shares":750000,"eps":0,"marketStatus":"盤前交易","change":0.0456,"latestTime":"09-17 08:25:53 EDT","open":41.8273,"high":41.8729,"low":41.8729,"amount":4036,"amplitude":0,"askPrice":66.99,"askSize":200,"bidPrice":16.75,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789651800000},"marketStatusCode":1,"adr":0,"exchange":"CBOE","adjPreClose":41.8729,"sharesOutstanding":650000,"nav":41.868,"aum":31401033.77,"dividendRate":0.003401,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":41.8273,"preClose":41.8729,"latestTime":"16:10 EDT","volume":6,"amount":251.1462,"timestamp":1789589404188,"change":-0.0456,"changeRate":-0.001089,"amplitude":0},"volumeRatio":0.24755027726791448,"impliedVol":0.0896,"impliedVolPercentile":0.344},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELX\",,,,,undefined,":{"symbol":"HELX","floatShares":750000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.24755027726791448,"shares":750000,"dividePrice":0.1424,"high":41.8729,"amplitude":0,"preClose":41.8273,"low":41.8729,"week52Low":29.8,"pbRate":"--","week52High":43.5089,"institutionHeld":0,"latestPrice":41.8729,"eps":0,"divideRate":0.003401,"volume":96,"delay":0,"ttmEps":0,"open":41.8273,"prevYearClose":36.3062,"prevWeekClose":40.9874,"prevMonthClose":41.805,"prevQuarterClose":39.9651,"fiveDayClose":41.5531,"twentyDayClose":40.9918,"sixtyDayClose":36.3258},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HELX\",params:#limit:5,,,undefined,":[{"date":"2025-12-30","symbol":"HELX","amount":0.14334,"announcedDate":"2025-12-29","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-30","defaultRemindTime":1767105000000,"name":"Franklin Genomic Advancements ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-08","payableDate":"2025-12-30","currency":"USD","dateTimestamp":1767070800000,"payDate":"2026-01-08"},{"market":"US","date":"2021-12-30","symbol":"HELX","amount":0.003935,"defaultRemindTime":1640874600000,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2022-01-07","payableDate":"2021-12-31","currency":"USD","type":"dividend","dateTimestamp":1640840400000},{"market":"US","date":"2021-12-13","symbol":"HELX","amount":0.114148,"defaultRemindTime":1639405800000,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2021-12-21","payableDate":"2021-12-14","currency":"USD","type":"dividend","dateTimestamp":1639371600000},{"market":"US","date":"2020-12-14","symbol":"HELX","amount":0.005005,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2020-12-23","payableDate":"2020-12-15","currency":"USD","type":"dividend","dateTimestamp":1607922000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HELX\",market:\"US\",,,undefined,":[{"executeDate":"2020-12-14","recordDate":"2020-12-15","paymentDate":"2020-12-23","value":0.005005,"currency":"USD"},{"executeDate":"2021-12-13","recordDate":"2021-12-14","paymentDate":"2021-12-21","value":0.114148,"currency":"USD"},{"executeDate":"2021-12-30","recordDate":"2021-12-31","paymentDate":"2022-01-07","value":0.003935,"currency":"USD"},{"executeDate":"2025-12-30","recordDate":"2025-12-30","paymentDate":"2026-01-08","value":0.14334,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HELX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HELX\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1160211496","title":"Twinstrand：法院判決公司及Uw獲賠逾2.452億美元，涵蓋截至2026年5月31日的侵權損害賠償、應計特許權使用費及利息","url":"https://stock-news.laohu8.com/highlight/detail?id=1160211496","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160211496?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 19:01","pubTimestamp":1787569302,"startTime":"0","endTime":"0","summary":"Twinstrand公告，法院已作出裁决，判令公司及Uw获得超过2.452亿美元的赔偿金。这笔款项涵盖了截至2026年5月31日期间所发生的侵权损害、累积的特许权使用费以及相应利息。\n裁决金额之巨，彰显了司法体系对知识产权保护的坚定立场。赔偿总额精确计算至该截止日期，包括了多层次的补偿要素。侵权行为的认定范围，则明确划定在2026年5月31日之前发生的全部相关行为。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FFOX","BK4196","HELX","EKG","LFSC","GNOM","PTH","BK4551","GDOC","LU0320765992.SGD","GNMX","BK4588","BK4535","GH","LU0109394709.USD","BK4585","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194764905","title":"Twinstrand勝訴：法院維持2023年故意侵權判決，並裁定Guardant Health 11項產品與服務須支付6%特許權使用費","url":"https://stock-news.laohu8.com/highlight/detail?id=1194764905","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194764905?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 19:01","pubTimestamp":1787569276,"startTime":"0","endTime":"0","summary":"法院裁定，维持2023年关于故意侵权的判决，同时要求Guardant Health公司就其11项产品及服务所产生的销售额，向Twinstrand支付6%的特许权使用费。这一裁决意味着，Twinstrand在知识产权纠纷中取得了关键性胜利。对于Guardant Health而言，这项决定无疑构成了财务上的重大负担。Twinstrand方面则对这一结果表示认可。此次6%特许权使用费的设定，亦反映了法院对此类行为的态度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","HELX","FFOX","GNOM","LU0109394709.USD","GDOC","PTH","GH","LU0889565916.HKD","BK4588","BK4535","GNMX","BK4196","EKG","LU0320765992.SGD","BK4551","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127912643","title":"Twinstrand案判決：Guardant Health須按季度向公司及承銷商彙報11款產品與服務的全美銷售明細","url":"https://stock-news.laohu8.com/highlight/detail?id=1127912643","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127912643?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 19:00","pubTimestamp":1787569211,"startTime":"0","endTime":"0","summary":"根据Twinstrand方面的消息，法院判决要求Guardant Health必须履行一项新的义务——按季度提交其在美国市场上全部11款产品与服务的销售账目，以供公司与承销商查阅。\n这一判决意味着，Guardant Health在运营透明度和合规性上将面临更为严格的监督。具体而言，公司需定期整理并呈报相关销售数据，确保各方能够及时掌握其业务动态。\n此举无疑为市场参与者提供了更清晰的视角，去审视这家精准医疗领域领军企业的真实业绩表现。季度汇报机制的建立，或将进一步影响投资者对该公司未来走势的评估与判断。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","BK4535","GDOC","BK4588","EKG","FFOX","HELX","GNMX","GNOM","LFSC","PTH","LU0109394709.USD","GH","LU0889565916.HKD","BK4551","LU0320765992.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136746995","title":"Twinstrand：特拉華州法院於8月21日裁定公司及華盛頓大學在針對Guardant Health的專利侵權訴訟中勝訴","url":"https://stock-news.laohu8.com/highlight/detail?id=1136746995","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136746995?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 19:00","pubTimestamp":1787569211,"startTime":"0","endTime":"0","summary":"Twinstrand宣布，特拉华州法院已于8月21日作出判决，支持公司及华盛顿大学的立场，认定其在针对Guardant Health提起的专利侵权诉讼中占据优势。这一裁决标志着这场备受关注的法律纠纷取得了阶段性胜利。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH","LU0320765992.SGD","GDOC","FFOX","BK4196","HELX","BK4585","LU0109394709.USD","PTH","LU0889565916.HKD","GNOM","GNMX","BK4588","BK4551","EKG","LFSC","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660790477","title":"A股異動 | 華大智造(688114.SH)早盤漲20%封漲停 基因測序有望成為mRNA個性化腫瘤疫苗「底層基礎設施「","url":"https://stock-news.laohu8.com/highlight/detail?id=2660790477","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660790477?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 10:36","pubTimestamp":1787193395,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，华大智造开盘后快速封涨停。截至发稿，涨20%，报69.11元，成交额4.28亿元。消息面上，Moderna与默沙东联合研发的个性化mRNA癌症疫苗在大型三期临床试验中取得成功，引爆全球mRNA肿瘤疫苗赛道。这意味着，基因测序作为个性化肿瘤疫苗\"底层基础设施\"的价值，正迎来战略重估。公开资料显示，华大智造为国产基因测序龙头。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482415.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["GDOC","HTEC","83188","83130","688114","GNMX","07233","BK1147","BK0251","02827","HELX","03130","02846","159982","82846","SYNB","03188","WDNA","159646","399300","GNOM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660421558","title":"第3次更新-足球——謝菲爾德聯隊前所有者獲准申請清算當初收購該俱樂部的那家公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2660421558","media":"路透中文","labels":["policyRegulatory","merge","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660421558?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 22:49","pubTimestamp":1787150961,"startTime":"0","endTime":"0","summary":"第3次更新-足球——谢菲尔德联队前所有者获准申请清算当初收购该俱乐部的那家公司在第4至5段中补充了谢菲尔德联队的声明路透伦敦8月19日-谢菲尔德联队前所有者周三获准申请，将清算该公司——该公司在2024年收购了这支英冠球队。谢菲尔德联队表示，高等法院的裁决对俱乐部而言并非问题。但今年6月，谢菲尔德联队表示1919 Partners LLC是该俱乐部的母公司，对此，United World本周表示，此举“似乎是试图逃避向CSBL的债权人付款”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nL4S44G1AH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory,merge,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH","EKG","GNOM","LU0109394709.USD","BK4535","LU0889565916.HKD","LU0320765992.SGD","BK4551","LFSC","BK4196","BK4585","GDOC","GNMX","BK4588","FFOX","PTH","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172077351","title":"Natera助力新臨床研究：利用Latitude™評估晚期皮膚癌ctDNA動態變化","url":"https://stock-news.laohu8.com/highlight/detail?id=1172077351","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172077351?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 18:02","pubTimestamp":1786528935,"startTime":"0","endTime":"0","summary":"Natera将支持一项全新临床试验，旨在评估Latitude™技术在晚期皮肤癌中监测循环肿瘤DNA（ctDNA）动态变化的能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2264538146.SGD","NTRA","LU2065169927.USD","LU0012050646.USD","LU2065171311.SGD","BK4139","LU2065170008.USD","LU2065731478.USD","LU2324357040.USD","LU0963586101.USD","HELX","LU1064131342.USD","LU0053671581.USD","LU0345770993.USD","GNOM","LU0345770308.USD","LU2065171402.SGD","LU0106261612.USD","LU1988902786.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658292607","title":"韓國公布七項戰略技術項目 涵蓋核能、量子計算、太空、生物技術等領域","url":"https://stock-news.laohu8.com/highlight/detail?id=2658292607","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658292607?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 14:07","pubTimestamp":1786514821,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["CHPX","CRTC","BK4585","QPUX","QTUM","XQTM","URNJ","QUA","WQTM","NLR","QTUP","BK4606","BK4588","SRUUF","NUKZ","SPRX","WDNA","URA","URAN","URNM","HELX","LOUP","CQTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658595928","title":"我國綠色燃料產業從「示範試點」走向「規模量產」","url":"https://stock-news.laohu8.com/highlight/detail?id=2658595928","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658595928?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 10:14","pubTimestamp":1786500840,"startTime":"0","endTime":"0","summary":"郭晓波认为，2026至2030年是我国绿色燃料产业从示范试点走向规模化应用的关键窗口期，当前绿色燃料市场已进入政策与需求“双轮”驱动阶段，碳价上行将持续收窄绿色燃料与传统燃料的价差。龙基能源集团致力于打破成本与效率“瓶颈”，助力我国绿色燃料产业从“示范试点”走向“规模量产”，为填补国内高端绿色航煤产能缺口贡献核心力量。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-08-12/doc-inimzivu5413675.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["WDNA","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658550947","title":"中賦科技成立靈源生物技術公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2658550947","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658550947?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 09:35","pubTimestamp":1786498517,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["WDNA","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658677969","title":"風暴眼 | 6歲女童基因治療死亡：急於追逐「全球首例」的代價","url":"https://stock-news.laohu8.com/highlight/detail?id=2658677969","media":"凤凰网港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658677969?lang=zh_tw&edition=fundamental","pubTime":"2026-08-09 21:40","pubTimestamp":1786282855,"startTime":"0","endTime":"0","summary":"事件背后，关于基因编辑与“追逐全球首例”的风险、其中的伦理边界之争，才刚刚开始。一周后，小美死亡。患者家属为试验和治疗自费的巨额花销，是另一重争议。“世界首例”的光环，的确十分诱人。也许是低估了高剂量AAV的免疫反应风险，也许是“全球首例”的诱惑压过了审慎，小美在时机尚不成熟的时候，被推上了手术台。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.ifeng.com/c/8vSOZR7YZVA","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HELX","NBDS","SYNB","TARK","BK4079","WDNA","IDNA","BK4168","BMED","AAMC","DTEC","FWD","XT","BK4139","KOMP","AAU","GNOM","ARDS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657695946","title":"半月內兩起兒童基因編輯試驗死亡事件曝光，業內警示：追求「全球首創」不能忽視臨床安全與合規要求","url":"https://stock-news.laohu8.com/highlight/detail?id=2657695946","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657695946?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 12:00","pubTimestamp":1786075247,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HELX","SYNB","IDNA","GNOM","BMED","XT","KOMP","DTEC","NBDS","FWD","TARK","WDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657413405","title":"新聞8點見丨影院屏攝亂象背後的三角困局；女童基因編輯悲劇中倫理為何失守","url":"https://stock-news.laohu8.com/highlight/detail?id=2657413405","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657413405?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 19:31","pubTimestamp":1785929460,"startTime":"0","endTime":"0","summary":"新闻8点见，多一点洞见。世界卫生组织临时专家组成员、世界卫生组织人类基因编辑治理和监督全球标准专家咨询委员会成员、国家科技伦理委员会委员翟晓梅。本次被广泛关注和报道的事件属于体细胞基因编辑。8月5日，中国气象局发文回应称，高温低报或高温不报是不存在的。体感温度和预报气温的差异，或许是人们质疑的原因。","market":"us","thumbnail":"https://media.bjnews.com.cn/cover/2026/08/05/5749141873621018263.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/cover/2026/08/05/5749141873621018263.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1785925616129444.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1785925616129444.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["WDNA","IDNA","SYNB","KOMP","HELX","FWD","BMED","DTEC","TARK","GNOM","XT","NBDS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656584164","title":"AI賦能肺癌早篩診療升級 國產醫療機器人加速精準醫療落地 真健康醫療(02697)迎行業發展機遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2656584164","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656584164?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 12:58","pubTimestamp":1785819500,"startTime":"0","endTime":"0","summary":"业内人士认为，随着AI影像识别、三维重建、机器人辅助介入等技术持续成熟，医疗机器人产业正加速迈入商业化应用阶段，覆盖肺癌、骨科、神经外科等多个高价值赛道，行业成长空间广阔。受益于医疗智能化升级趋势，“穿刺手术机器人第一股”真健康医疗持续推进人工智能与数字医疗布局。随着国家持续推动医疗数字化建设，以及AI医疗机器人、精准诊疗等新技术加速落地，真健康医疗有望受益于行业景气度提升，进一步打开长期成长空间。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475645.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AGIX","ARTY","DTEC","HELX","AIPO","XT","159891","BK1100","TYNE","CHAT","02697","GNMX","QTOC","WDNA","VTHR","HTEC","IDNA","GDOC","GNOM","KOMP","SYNB","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656585241","title":"港股異動 | 凱萊英升逾8%，近日擬向上海凱萊英生物技術發展增資10.5億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2656585241","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656585241?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 09:35","pubTimestamp":1785807328,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，凯莱英高开逾5%，截至发稿，涨5.5%，报115港元，成交额319.7万港元。消息面上，近日，凯莱英发布公告，该公司、目标公司上海凯莱英生物技术发展有限公司、凯莱英生物技术、高瓴祈睿、珠海岱恒、Hao Hong博士、凯莱同心及海河凯莱英基金订立增资协议，据此，该公司及投资者同意向目标公司股本增资，总额为人民币12.397亿元，公司、高瓴祈睿、Hao Hong博士分别出资10.5亿元、1.77亿元及1270万元。","market":"hk","thumbnail":"https://static.tigerbbs.com/c5f6cd84096ca9b3b893fb788b76d134","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/c5f6cd84096ca9b3b893fb788b76d134"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475561.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0132","VXUS","HELX","WDNA","BK4585","BK0239","BK4588","LU1328615791.USD","002821","KCAI","BK1191","06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656303576","title":"專注腫瘤領域的生物技術公司BlossomHill Therapeutics計劃通過首次公開募股募資約1.328億美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2656303576","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656303576?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 00:41","pubTimestamp":1785775260,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LENZ","BK4139","WDNA","PEVC","IPO","BK4007","SPCK","ACSG","BCSM","LQPE","HELX","QQQS","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656037309","title":"基因編輯的商業化：一款產品220萬美元，A股超20家概念股，但多數只賣工具","url":"https://stock-news.laohu8.com/highlight/detail?id=2656037309","media":"红星资本局","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656037309?lang=zh_tw&edition=fundamental","pubTime":"2026-08-03 18:53","pubTimestamp":1785754410,"startTime":"0","endTime":"0","summary":"红星资本局8月3日消息，近日，一名6岁女童在接受基因编辑临床试验后死亡的事件，将“基因编辑”这项前沿技术推向公众视野。红星资本局注意到，近年来，基因编辑这一创新医疗技术在β-地中海贫血、镰状细胞贫血病等遗传性疾病治疗领域已有成熟应用，国外也有获批上市的药物。在国内，目前布局基因编辑疗法的主要为新兴的生物科技公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608033829926851.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608033829926851.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BMED","HELX","XT","SYNB","WDNA","GNOM","IDNA","TARK","399300","NBDS","KOMP","DTEC","159982","FWD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655389842","title":"市場消息：日本政府計劃將西日本打造為生物技術與高端醫藥領域的投資集聚中心。","url":"https://stock-news.laohu8.com/highlight/detail?id=2655389842","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655389842?lang=zh_tw&edition=fundamental","pubTime":"2026-07-31 04:50","pubTimestamp":1785444630,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["WDNA","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655803495","title":"凱萊英(06821)擬向上海凱萊英生物技術發展增資10.5億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2655803495","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655803495?lang=zh_tw&edition=fundamental","pubTime":"2026-07-30 21:53","pubTimestamp":1785419628,"startTime":"0","endTime":"0","summary":"智通财经APP讯，凯莱英 公布，于2026年7月30日，该公司、目标公司上海凯莱英生物技术发展有限公司、凯莱英生物技术、高瓴祈睿、珠海岱恒、Hao Hong博士、凯莱同心及海河凯莱英基金订立增资协议，据此，该公司及投资者同意向目标公司股本增资，总额为人民币12.397亿元，公司、高瓴祈睿、Hao Hong博士分别出资10.5亿元、1.77亿元及1270万元。于增资完成后，目标公司将由公司拥有约83.50%的权益，并仍为公司的非全资附属公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474299.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06821","HELX","002821","BK0239","BK0132","WDNA","BK1191","LU1328615791.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655491803","title":"凱萊英(06821.HK)擬向上海凱萊英生物技術發展增資10.5億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2655491803","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655491803?lang=zh_tw&edition=fundamental","pubTime":"2026-07-30 21:53","pubTimestamp":1785419628,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HELX","WDNA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":56,"code":"91000000","status":"200"}]}}